论文部分内容阅读
目的探讨131I联合甘氨双唑钠治疗分化型甲状腺癌(DTC)骨转移108例患者的疗效。方法以DTC伴骨转移患者108例为研究对象,随机分成观察组和对照组,对照组仅予131I治疗,观察组予131I联合甘氨双唑钠治疗,比较2组临床疗效、生存率及药物不良反应。结果按照骨痛评价标准,观察组的有效率(72.22%)显著高于对照组(53.70%),差异有统计学意义(P<0.05)。按照血清甲状腺球蛋白(Tg)评价标准,观察组的有效率(81.48%)显著高于对照组(62.96%),差异有统计学意义(P<0.05)。观察组5年生存率(75.93%)显著高于对照组(55.56%),差异有统计学意义(χ2=4.974,P=0.05)。2组不良反应发生率,差异无统计学意义(P>0.05)。结论131I联合甘氨双唑钠可提高DTC伴骨转移患者临床疗效,提高生存率。
Objective To investigate the curative effect of 131I combined with glycididazole on 108 patients with differentiated thyroid carcinoma (DTC) bone metastasis. Methods One hundred and eight patients with DTC with bone metastasis were randomly divided into observation group and control group. The control group received only 131I treatment. The observation group received 131I combined with glycopyrrolate sodium. The clinical efficacy, survival rate, Adverse reactions. Results According to the evaluation criteria of bone pain, the effective rate of the observation group (72.22%) was significantly higher than that of the control group (53.70%), the difference was statistically significant (P <0.05). According to the criterion of serum thyroglobulin (Tg), the effective rate of observation group (81.48%) was significantly higher than that of control group (62.96%), the difference was statistically significant (P <0.05). The 5-year survival rate (75.93%) in the observation group was significantly higher than that in the control group (55.56%), the difference was statistically significant (χ2 = 4.974, P = 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion 131I combined with glycopyrrolate sodium can improve the clinical efficacy of DTC with bone metastasis and improve the survival rate.